Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

The conclusion of the conversation is that the user, djamezz, has experienced significant regrowth and improved density in their hairline by using treatments such as RU (RU58841), dut (dutasteride), and Inkey's Caffeine Scalp treatment. They are satisfied with their progress and do not plan to cut off their hair.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

The conversation discusses hair transplants, including the use of techniques like FUE and the importance of a good donor area to avoid visible bald patches. It also touches on alternative treatments like Minoxidil, Finasteride, and Pyrolutimide, and debates the idea of embracing baldness versus seeking treatments.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

User accepted hair loss, shaved head, and feels free. Others joke about confusing photo angles.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Excessive scalp sebum, worsened by DHT, can lead to inflammation and hair loss, with clascoterone mentioned as a treatment. Diet changes seem ineffective for scalp sebum, and treatments like minoxidil and finasteride are suggested.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

The conversation is about the potential format of Breezula, a hair loss treatment, and concerns that it might be greasy or sticky. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

The conversation is about managing an itchy, flaky scalp, possibly due to psoriasis, and the use of a hydrating conditioner to address dryness. The user is concerned about using conditioner due to experiencing telogen effluvium.

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

User hides baldness with side hair growth, others suggest it looks good but may not work in all conditions. Some recommend starting treatment or considering a hair transplant.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conclusion of the conversation is that the user has decided to embrace their hair loss and has buzzed their head. They plan to continue their current hair loss treatments until they run out of stock. They also mention having dandruff and will continue medication for that.

A 23-year-old male is using topical minoxidil and oral finasteride for hair regrowth, noticing some progress on his temples and seeking advice on whether this indicates overall scalp improvement. Users suggest patience, as regrowth can take time, and advise against a hair transplant, noting that the current treatment seems effective.

Cyperus rotundus oil is suggested as a natural treatment for androgenic alopecia, potentially inhibiting hair growth without affecting testosterone levels. The conversation questions its effectiveness and safety for scalp use.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation humorously discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. The user jokes about the obvious signs of balding.

The conversation discusses concerns about importing Koshine KX, a hair loss treatment. A user reassures that there is no risk of getting caught.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.